Special Report: Navigating the second medical use landscape

In recent years, second medical use patents have been the subject of myriad litigations and a selection of interesting decisions across many jurisdictions has resulted. 

LSPN Connect  recently tackled this tricky and timely topic  with Sheldon Hamilton, partner, Smart & Biggar; Shahan Islam, senior counsel for patents, Pfizer; John Liddicoat, senior research associate, University of Cambridge; Jackie Mulryne, partner, Arnold & Porter; and Justin Turner, QC, Three New Square Chambers, and has published a special report based on their discussion.

Enter your details into the form now to access the special report  

Access the report now for:
● In-depth analysis of the significance of second medical use patents on pharmaceutical R&D

● Expert opinion on the consequences and complications from Warner-Lambert v Actavis 

● Exclusive insight into the regulatory environment for second medical use patents and how this regulation can be used to assist in their protection 

● Strategies that pharmaceutical companies can adopt to mitigate cross-label use without resorting to patent enforcement.

Enter your details into the form now to access the special report  


Use the form to download the special report

Enter your details below to access the special report now

This report is produced by Newton Media. By registering to view the publication, you agree to share your contact information with Newton Media. Full details of our privacy policy can be found here.